Takeda pulls two diabetes drugs off French market
OSAKA, Japan — Two diabetes drugs made by Takeda Pharmaceutical Co. have been pulled from the market in France due to evidence that their use may increase the risk of bladder cancer, Takeda said.
Takeda said its French subsidiary, Laboratoires Takeda, would withdraw Actos (pioglitazone) and Competact (pioglitazone and metformin). In addition, Takeda said it was cooperating with the European Medicines Agency in a pan-European of pioglitazone. Competact is marketed in the United States under the brand name Actoplus Met.
In June, the Food and Drug Administration warned that use of pioglitazone for more than one year could be associated with an increased risk of bladder cancer, and the agency said information about the risk would be added to the labeling of products containing the drug, which remains available in the United States.
Eli Lilly & Co., Disney partner to create lifestyle media for families affected by Type 1 diabetes
INDIANAPOLIS — Eli Lilly & Co. and Disney are collaborating to produce a dedicated lifestyle website and publications for families affected by Type 1 diabetes, the two companies said Thursday.
Lilly Diabetes announced the launch of a partnership with Disney Online and Disney Publishing Worldwide to provide inspiration, education and practical advice to families with children who have the disease. Resources include a special hub at Family.com/Type1 and a series of custom books by Disney’s publishing arm for children of various ages and stages of life with diabetes.
More than 13,000 young people are diagnosed every year in the United States with Type 1 diabetes, an autoimmune disorder formerly known as childhood-onset diabetes.
Bayer HealthCare study suggests acne treatment may help sufferers with postinflammatory hyperpigmentation
BERLIN — A new study conducted by Bayer HealthCare suggests that an investigational treatment for acne may be suitable for patients with dark complexions whose acne includes a condition that causes irregular discoloration of the skin known as postinflammatory hyperpigmentation, or PIH.
In the study, published in the Journal of Drugs in Dermatology, patients received azelaic acid in the 15% strength. Patients with dark skin are at increased risk of PIH, which is a widespread side effect of acne vulgaris, and also may result from skin irritation. Bayer and Intendis market the drug around the world under the brand names Skinoren and Finacea.
By the end of the study, in the 16th week, all patients showed at least a “one-grade improvement” in their PIH, while 92% showed a “two-grade improvement” and 31% had complete clearance of PIH.